Research showed that glucagon co-agonism increased hepatic fat oxidation and thermogenesis, providing an additional fat-loss mechanism distinct from appetite suppression alone
This page is written for research-only interpretation and does not provide dosing, clinical, diagnostic, therapeutic, veterinary, or human-use guidance
GoalBMI Wellness offers physician-supervised BPC-157 peptide therapy programs designed around individualized provider evaluation, wellness goals, recovery support, and treatment eligibility
Match decentralization strategy to trial type, rather than assuming a one-size-fits-all approach across behavioral, device, and drug trials
However, ongoing research is needed to better understand how these findings translate to human health outcomes